New drug combo tested for Tough-to-Treat breast cancer
Disease control
Recruiting now
This study is testing whether combining two drugs, tinengotinib and fulvestrant, can help control advanced breast cancer that has stopped responding to standard hormone therapies. It will involve about 94 people with HR-positive, HER2-negative or low-expressing breast cancer that…
Phase: PHASE2 • Sponsor: TransThera Sciences (Nanjing), Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:40 UTC